Cancer Biomarkers Market

The global market for cancer biomarkers is projected to reach USD 54.48 billion by 2032 from USD 28.25 billion in 2026. Factors contributing to the growth of this market include rising cancer cases, advances in technology for cancer biomarker development, research and development activities focused on cancer biomarkers, and increased use of cancer biomarkers in drug discovery and development. On the other hand, costs associated with different types of cancer diagnostic tests, the need for substantial investment, poor reimbursement policies, and technical challenges in sample handling hinder market growth.

In April 2025, Roche was granted FDA Breakthrough Device Designation for the VENTANA TROP2 (EPR20043) RxDx Device. This was a massive milestone as it is the first AI-driven computational pathology companion diagnostic device, used to identify non-small cell lung cancer (NSCLC) patients eligible for DATROWAY.

To know about the assumptions considered for the study download the pdf brochure

In January 2026, Thermo Fisher received FDA approval to expand the indications for its flagship Ion Torrent Oncomine Dx Target Test. This is a crucial multi-biomarker next-generation sequencing (NGS) in-vitro diagnostic used globally to evaluate patient tumor samples and match them with specific targeted therapies, particularly for non-small cell lung cancer (NSCLC) and cholangiocarcinoma.

Some of the major players in the cancer biomarkers market with significant global presence include Roche (Switzerland), Thermo Fisher (US), Illumina (US), Agilent Technologies (US), and QIAGEN (Netherlands), among others. The companies have pursued a number of strategies, such as product launches and expansions, to strengthen their global presence and increase their market share in the global cancer biomarkers market. The strategies have helped companies gain a presence in different regions of the world by providing high-class cardiac biomarker testing solutions and services.

In 2023, F. Hoffmann-La Roche Ltd. held the leading position in the cancer biomarkers market. The company has strong distribution networks across Europe, the Middle East & Africa, North America, and Asia Pacific. To sustain its leading position in the market, the company pursues organic growth strategies. For example, in January 2021, the company launched uPath HER2 (4B5) image analysis and uPath HER2 Dual ISH image analysis algorithms (assays & kits) for precision patient diagnosis of breast cancer.

Thermo Fisher (US) is a prominent player in the cancer biomarkers market, thanks to its strong presence in the US and ongoing efforts to expand its footprint in emerging markets. Thermo has a strong product portfolio in terms of cancer biomarker tests, with some of its products being approved by regulatory authorities such as the U.S. FDA and CE marked, thereby contributing to its strong share in the market. Thermo has been making efficient use of strategic partnerships, acquisitions, and collaborations to enhance its product offerings and geographical presence. In addition, Thermo's efforts to strengthen its position in the cancer biomarkers market will be driven by its continuous efforts to enhance its research and development capabilities, along with a strong pipeline and clinical validation of its assays.

Market Ranking

Roche (Switzerland) has a dominant share in the cancer biomarkers market due to its wide range of high-sensitivity cancer biomarkers and diagnostic platforms. Thermo Fisher (US) holds a significant share of the cancer biomarkers market, offering a broad portfolio of assays, software, and services under its Oncomine brand. Illumina (US) further strengthens its foothold in the cancer biomarkers market through its advanced NGS technology platforms and focuses on organic and inorganic strategies to strengthen its position in the market. Similarly, Agilent Technologies (US) makes a significant contribution to the cancer biomarkers market through its advanced diagnostic technology platforms and focuses heavily on both organic and inorganic strategies to strengthen its market position. QIAGEN (Netherlands) also plays a vital role in the cancer biomarkers market through its quality control solutions for precise cancer biomarker testing.

Related Reports:

Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma), Product (Instruments, Consumables), Application (Diagnostics, R&D), End User (Diagnostic Laboratories), And Region - Global Forecast to 2032

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]